Patient perceptions associated with the 5% lidocaine medicated plaster in daily practice

References

• Reid KJ, Harker J, Bala MM, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin 2011;27:449-62
   PubMed Web of Science ®Google Scholar
• Haanpää M, Backonja MM, Bennett M, et al. Assessment of neuropathic pain in primary care. Am J Med 2009;122(Suppl 10):S13-21
   PubMed Web of Science ®Google Scholar
• Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9:807-19
   PubMed Web of Science ®Google Scholar
• Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-5
   PubMed Web of Science ®Google Scholar
• International Association for the Study of Pain: Part III: Pain Terms, A Current List with Definitions and Notes on Usage (pp 209-214) Classification of Chronic Pain, 2nd Edn, IASP Task Force on Taxonomy, edited by H. Merskey and N. Bogduk, IASP Press, Seattle, 1994: 2011 update available at: http://www.iasp-pain.org/AM/Template.cfm?Section=Pain_Defi…isplay.cfm&ContentID=1728#Neuropathicpain [Last accessed 26th April 2012]
   Google Scholar
• Smith BH, Torrance N. Epidemiology of neuropathic pain. Pain Manage 2011;1:87-96
   PubMedGoogle Scholar
• Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573-81
   PubMed Web of Science ®Google Scholar
• O’Connor AB. Neuropathic pain. Quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 2009;27:95-112
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Otto M, Jensen TS, et al. An evidence-based algorithm for the treatment of neuropathic pain. Medsc Gen Med 2007;9:36
   PubMedGoogle Scholar
• Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(3 Suppl):S3-14
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65:39-44
   PubMed Web of Science ®Google Scholar
• Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999;80:533-8
   PubMed Web of Science ®Google Scholar
• Baron R, Mayoral V, Leijon G, et al. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 2009;25:1663-76
   PubMed Web of Science ®Google Scholar
• Binder A, Bruxelle J, Rogers P, et al. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig 2009;29:393-408
   PubMed Web of Science ®Google Scholar
• Rehm S, Binder A, Baron R. Post-herpetic neuralgia – 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin 2010;26:1607-19
   PubMed Web of Science ®Google Scholar
• Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003;106:151-8
   PubMed Web of Science ®Google Scholar
• Argoff CE, Galer BS, Jensen MP, et al. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the neuropathic pain scale. Curr Med Res Opin 2004;20(Suppl 2):S21-8
   PubMed Web of Science ®Google Scholar
• Barbano RL, Herrmann DN, Hart-Gouleau S, et al. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004;61:914-18
   PubMed Web of Science ®Google Scholar
• Herrmann DN, Barbano RL, Hart-Gouleau S, et al. An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy. Pain Med 2005;6:379-84
   PubMed Web of Science ®Google Scholar
• Hans G, Joukes E, Verhulst J, et al. Management of neuropathic pain after surgical and non-surgical trauma with lidocaine 5% patches: study of 40 consecutive cases. Curr Med Res Opin 2009;25:2737-43
   PubMed Web of Science ®Google Scholar
• Galer BS, Gammaitoni AR. More than 7 years of consistent neuropathic pain relief in geriatric patients. Arch Intern Med 2003;163:628
   PubMed Web of Science ®Google Scholar
• Hans G, Sabatowski R, Binder A, et al. Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. Curr Med Res Opin 2009;25:1295-305
   PubMed Web of Science ®Google Scholar
• Wilhelm IR, Tzabazis A, Likar R, et al. Long-term treatment of neuropathic pain with a 5% lidocaine medicated plaster. Eur J Anaesthesiol 2010;27:169-73
   PubMed Web of Science ®Google Scholar
• Delorme C, Navez ML, Legout V, et al. Treatment of neuropathic pain with 5% lidocaine-medicated plaster: five years of clinical experience. Pain Res Manage 2011;16:259-62
   PubMed Web of Science ®Google Scholar
• Correa-Illanes G, Calderón W, Roa R, et al. Treatment of localized post-traumatic neuropathic pain in scars with 5% lidocaine medicated plaster. Local Reg Anesth 2010;3:77-83
   PubMedGoogle Scholar
• Clère F, Delorme-Morin C, George B, et al. 5% lidocaine medicated plaster in elderly patients with postherpetic neuralgia – results of a compassionate use programme in France. Drugs Aging 2011;28:693-702
   PubMed Web of Science ®Google Scholar
• Kern KU, Kohl M, Kiefer RT. Lidocaine patch for therapy of neuropathic and non-neuropathic pain: a clinical case series of 87 patients [in German]. Nervenarzt 2010;81:1490-7
   PubMed Web of Science ®Google Scholar
• Nagel B, Gerbershagen HU, Lindena G, et al. Development and evaluation of the multidimensional German pain questionnaire [in German]. Schmerz 2002;16:263-70
   PubMed Web of Science ®Google Scholar
• Müller-Schwefe G, Zenz M (eds.) The German Pain Questionnaire. German Pain Association, 2006. ISBN: 3-00-017-440-0 (in German)
   Google Scholar
• Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19
   PubMed Web of Science ®Google Scholar
• Basler HD. The Marburg questionnaire for habitual well-being [in German]. Schmerz 1999;13:385-91
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70
   PubMed Web of Science ®Google Scholar
• Tait RC, Chibnall JT, Krause S. The pain disability index: psychometric properties. Pain 1990;40:171-82
   PubMed Web of Science ®Google Scholar
• Müller-Schwefe GHH, Überall MA. Pain and quality of life [in German]. Gesundh ökon Qual manag 2011;16:S20-22
   Google Scholar
• Weber J, Schley M, Casutt M, et al. Tetrahydrocannabinol (delta 9-THC) treatment in chronic central neuropathic pain and fibromyalgia patients: results of a multicenter survey. Anesthesiol Res Pract 2009;827290
   PubMedGoogle Scholar
• Gerbershagen HU. The Mainz Staging System for chronic pain. In: Klinger D, et al (eds). Antidepressives as Analgesics. Linz: Arachne, 1996:71-95 [in German]
   Google Scholar
• Electronic Medicines Compendium. Versatis 5% medicated plaster. Summary of Product Characteristics. Available at: http://emc.medicines.org.uk/medicine/19291/SPC/Versatis+5%25+Medicated+Plaster [Last accessed 30 September 2010]
   Google Scholar
• Freynhagen R, Baron R, Gockel U, et al. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911-20
   PubMed Web of Science ®Google Scholar
• Wolff RF, Bala MM, Westwood M, et al. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly 2010;140:297-306
   PubMed Web of Science ®Google Scholar
• Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009;35:206-13
   PubMed Web of Science ®Google Scholar
• Galer BS, Gammaitoni AR, Oleka N, et al. Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain. Curr Med Res Opin 2004;20(Suppl 2):S5-12
   PubMed Web of Science ®Google Scholar
• Gimbel J, Linn R, Hale M, et al. Lidocaine patch treatment in patients with low back pain: results of an open-label, nonrandomized pilot study. Am J Ther 2005;12:311-19
   PubMedGoogle Scholar
• Gwilym SE, Keltner JR, Warnaby CE, et al. Psychophysical and functional imaging evidence supporting the presence of central sensitization in a cohort of osteoarthritis patients. Arthritis Rheum 2009;61:1226-34
   PubMed Web of Science ®Google Scholar
• Burch F, Codding C, Patel N, et al. Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial. Osteoarthritis Cartilage 2004;12:253-5
   PubMed Web of Science ®Google Scholar
• Gammaitoni AR, Galer BS, Onawola R, et al. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the neuropathic pain scale. Curr Med Res Opin 2004;20(Suppl 2):S13-18
   PubMed Web of Science ®Google Scholar
• Nicolaou A, Nicholson B, Hans G, et al. Outcome predictors for treatment success with 5% lidocaine medicated plaster in low back pain with neuropathic components and neuropathic pain after surgical and non-surgical trauma. J Pain Res 2011;4:25-38
   PubMedGoogle Scholar